[HTML][HTML] Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a …
M Westwood, M Joore, P Whiting… - Health Technology …, 2014 - ncbi.nlm.nih.gov
BACKGROUND Non-small cell lung cancer (NSCLC) is the most common form of lung
cancer. Some epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutations make …
cancer. Some epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutations make …
Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal
D Boyers, X Jia, D Jenkinson, G Mowatt - Pharmacoeconomics, 2012 - Springer
Abstract The National Institute for Health and Clinical Excellence (NICE) invited the
manufacturer of eltrombopag (GlaxoSmithKline) to submit evidence for the clinical and cost …
manufacturer of eltrombopag (GlaxoSmithKline) to submit evidence for the clinical and cost …
Omalizumab for the treatment of severe persistent allergic asthma in children aged 6–11 years: a NICE single technology appraisal
J Burch, S Griffin, C McKenna, S Walker, J Paton… - …, 2012 - Springer
Following a licence extension to include those aged 6–11 years, the National Institute for
Health and Clinical Excellence (NICE) invited the manufacturer of omalizumab (Novartis …
Health and Clinical Excellence (NICE) invited the manufacturer of omalizumab (Novartis …
Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma: a NICE single technology appraisal
Abstract The National Institute for Health and Clinical Excellence (NICE) invited the
manufacturer of pazopanib hydrochloride (GlaxoSmithKline) to submit evidence of the …
manufacturer of pazopanib hydrochloride (GlaxoSmithKline) to submit evidence of the …
Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal
G Scotland, N Waugh, P Royle, P McNamee… - …, 2011 - Springer
Abstract The National Institute for Health and Clinical Excellence (NICE) invited the
manufacturer of denosumab (Amgen Inc., UK) to submit evidence for the clinical and cost …
manufacturer of denosumab (Amgen Inc., UK) to submit evidence for the clinical and cost …
Economic considerations in the use of novel targeted therapies for lung cancer: review of current literature
Lung cancer remains the leading cause of cancer-related death and economic burden
worldwide. Despite the heavy toll of lung cancer, multiple new advances have improved …
worldwide. Despite the heavy toll of lung cancer, multiple new advances have improved …
Oral Vinorelbine plus Cisplatin as first-line chemotherapy in nonsquamous non–small-cell lung cancer: Final results of an international randomized phase II study …
J Bennouna, L Havel, M Krzakowski, J Kollmeier… - Clinical Lung Cancer, 2014 - Elsevier
Background The combination of oral vinorelbine plus cisplatin has been studied in
numerous trials as first-line treatment of patients with non–small cell lung cancer (NSCLC) …
numerous trials as first-line treatment of patients with non–small cell lung cancer (NSCLC) …
Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisal
B Kearns, M Lloyd Jones, M Stevenson… - Pharmacoeconomics, 2013 - Springer
Abstract The National Institute for Health and Clinical Excellence (NICE) invited the
manufacturer of cabazitaxel (Jevtana®, sanofi-aventis, UK) to submit evidence of its clinical …
manufacturer of cabazitaxel (Jevtana®, sanofi-aventis, UK) to submit evidence of its clinical …
Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal
Abstract The National Institute for Health and Clinical Excellence (NICE) invited the
manufacturer of bevacizumab (Roche Products) to submit evidence for the clinical and cost …
manufacturer of bevacizumab (Roche Products) to submit evidence for the clinical and cost …
Anti-tumor enhancement of Fei-Liu-Ping ointment in combination with celecoxib via cyclooxygenase-2-mediated lung metastatic inflammatory microenvironment in …
R Liu, H Zheng, W Li, Q Guo, S He, Y Hirasaki… - Journal of translational …, 2015 - Springer
Abstract Background Fei-Liu-Ping (FLP) ointment is an oral prescription medication that has
been widely applied to treat lung cancer patients in China. Regulation of the metastatic …
been widely applied to treat lung cancer patients in China. Regulation of the metastatic …